AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26335982 — intervention group
Group type: EXPERIMENTAL
Intervention: Postintervention alerts
Number of subjects: 171
Study 26335982 — intervention group
Group type: EXPERIMENTAL
Intervention: Postintervention EHR alerts
Number of subjects: 171
Study 24491609 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making intervention (n=13)
Number of subjects: 27
Study 24491609 — intervention group
Group type: COMPARATOR
Intervention: Usual care condition (n=14)
Number of subjects: 27
Study 21837450 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric exercise (PL group, n = 8)
Number of subjects: 24
Study 21837450 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent running (IR group, n = 8)
Number of subjects: 24
Study 21837450 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control (CON group, n = 8)
Number of subjects: 24
Study 19942724 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 26
Study 19942724 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthetic injection
Number of subjects: 26
Study 17470161 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly i.v. clodronate
Number of subjects: 94
Study 17470161 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly i.v. zoledronic acid
Number of subjects: 94
Study 17470161 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (control)
Number of subjects: 94
Study 15141904 — intervention group
Group type: EXPERIMENTAL
Intervention: Cup stacking program (5 weeks)
Number of subjects: 42
Study 15141904 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 42
Study 11234138 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (14 patients)
Number of subjects: 28
Study 11234138 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (14 patients)
Number of subjects: 28
Study 9487210 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir (1000 mg twice daily for 5 days)
Number of subjects: 1200
Study 9487210 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (200 mg 5 times daily for 5 days)
Number of subjects: 1200
Study 9487210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200
Study 8045141 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-1A (100 mg)
Number of subjects: 543
Study 8045141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 543
Study 3059756 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg of acetaminophen
Number of subjects: 263
Study 3059756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study 30442653 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pregabalin
Number of subjects: 0
Study 30442653 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl
Number of subjects: 0
Study 28196711 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive defusion
Number of subjects: 191
Study 28196711 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery
Number of subjects: 191
Study 28196711 — intervention group
Group type: COMPARATOR
Intervention: Mind-wandering (control)
Number of subjects: 191
Study 25420129 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated adventure-based training and health education program
Number of subjects: 69
Study 25420129 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 69
Study 22269473 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg mifepristone daily for 6 months
Number of subjects: 176
Study 22269473 — intervention group
Group type: EXPERIMENTAL
Intervention: 5mg mifepristone daily for 6 months
Number of subjects: 176
Study 22269473 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment follow-up at 12 months
Number of subjects: 176
Study 19895922 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Number of subjects: 619
Study 19895922 — intervention group
Group type: COMPARATOR
Intervention: MPSV4
Number of subjects: 619
Study 18035001 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorogenic acid enriched instant coffee
Number of subjects: 42
Study 18035001 — intervention group
Group type: COMPARATOR
Intervention: Normal instant coffee
Number of subjects: 42
Study 15663703 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialty care payment carve-out from Medicaid managed care
Number of subjects: 0
Study 15663703 — intervention group
Group type: COMPARATOR
Intervention: Children in managed care counties who were not mandated to enroll
Number of subjects: 0
Study 15663703 — intervention group
Group type: COMPARATOR
Intervention: Children in nonmanaged care counties
Number of subjects: 0
Study 12085142 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Colon Resection (LCR)
Number of subjects: 83
Study 12085142 — intervention group
Group type: COMPARATOR
Intervention: Open Colon Resection (OCR)
Number of subjects: 83
Study 10432409 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral
Number of subjects: 262
Study 10432409 — intervention group
Group type: COMPARATOR
Intervention: Sandimmune
Number of subjects: 262
Study 7541235 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with PBPC support and G-CSF (12 or 30 micrograms kg‐1 day‐1 for 10 days)
Number of subjects: 10
Study 7541235 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with PBPC support and G-CSF
Number of subjects: 10
Study 2386358 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous interscalene brachial plexus block with 0.75% bupivacaine (150‐210 mg) with adrenaline, followed by an infusion of 0.25% bupivacaine 0.25 mg/kg/h
Number of subjects: 40
Study 2386358 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia after starting a continuous interscalene brachial plexus block with a test dose of 0.75% bupivacaine (22.5 mg) with adrenaline, followed by an infusion of 0.25% bupivacaine 0.25 mg/kg/h
Number of subjects: 40
Study 2386358 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous interscalene brachial plexus block
Number of subjects: 40
Study 514425 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-enriched dialysate (400 mg/100 ml)
Number of subjects: 10
Study 31263024 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with bevacizumab (15 mg/kg every 3 weeks for ≥3 cycles)
Number of subjects: 68
Study 31263024 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy alone
Number of subjects: 68
Study 31263024 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with bevacizumab
Number of subjects: 68
Study 30293817 — intervention group
Group type: EXPERIMENTAL
Intervention: Dequalinium chloride
Number of subjects: 1
Study 30293817 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofoctol
Number of subjects: 1
Study 30293817 — intervention group
Group type: EXPERIMENTAL
Intervention: Dequalinium chloride and Clofoctol
Number of subjects: 1
Study 26270693 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleotide supplementation
Number of subjects: 20
Study 26270693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 24682080 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous sciatic nerve block (0.2% ropivacaine 5 mL/h)
Number of subjects: 60
Study 24682080 — intervention group
Group type: COMPARATOR
Intervention: Single-injection sciatic nerve block (0.2% ropivacaine 20 mL) with sham continuous SNB (0.9% normal saline 5 mL/h)
Number of subjects: 60
Study 22467087 — intervention group
Group type: COMPARATOR
Intervention: Local steroid injection
Number of subjects: 163
Study 22467087 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical decompression
Number of subjects: 163
Study 20955868 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 42
Study 20955868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 19020138 — intervention group
Group type: EXPERIMENTAL
Intervention: Blanket method
Number of subjects: 85
Study 19020138 — intervention group
Group type: COMPARATOR
Intervention: Table-ramp method
Number of subjects: 85
Study 19020138 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 85
Study 15943172 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive group treatment program (10-week, 30 hours)
Number of subjects: 105
Study 15943172 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 105
Study 15943172 — intervention group
Group type: COMPARATOR
Intervention: Comparison of treatment vs control at 18 months
Number of subjects: 105
Study 11898037 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy (5‐fluorouracil + cisplatin) with concomitant 45 Gray radiotherapy in a 5‐week course
Number of subjects: 61
Study 11898037 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (standard surgical group)
Number of subjects: 61
Study 11898037 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathologic complete response (pCR) group
Number of subjects: 61
Study 11898037 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathologic incomplete response (pIR) group
Number of subjects: 61
Study 10395845 — intervention group
Group type: EXPERIMENTAL
Intervention: Current standard therapy (2 nucleoside analogues and a protease inhibitor)
Number of subjects: 16
Study 7477616 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic gastroparesis (DGP) group
Number of subjects: 226
Study 2182236 — intervention group
Group type: EXPERIMENTAL
Intervention: Anistreplase (30 U administered intravenously within the first 6 hours)
Number of subjects: 0
Study 2182236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7372824 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory biofeedback of digital skin temperature (DST) during Increase trials
Number of subjects: 10
Study 7372824 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory biofeedback of digital skin temperature (DST) during Decrease trials
Number of subjects: 10
Study 7372824 — intervention group
Group type: COMPARATOR
Intervention: Baseline trials (no feedback)
Number of subjects: 10
Study 7372824 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease trials
Number of subjects: 10
Study 7372824 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase trials
Number of subjects: 10
Study 31472691 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous minimally invasive approach
Number of subjects: 0
Study 31472691 — intervention group
Group type: COMPARATOR
Intervention: Conventional open approach
Number of subjects: 0
Study 28472499 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy Management Service (PharMS)
Number of subjects: 157
Study 27199158 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grain bread
Number of subjects: 11
Study 27199158 — intervention group
Group type: COMPARATOR
Intervention: Conventional bread
Number of subjects: 11
Study 23432528 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim (mean 5-8 μg/kg, self-administered at home)
Number of subjects: 292
Study 23432528 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 292
Study 21347869 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose selenium supplementation (Se+ group, n = 75) - 1,000 μg on day 1, 500 μg/day on days 2-14
Number of subjects: 150
Study 21347869 — intervention group
Group type: COMPARATOR
Intervention: Standard selenium dose (<75 μg/day) in control group (Se- group, n = 75)
Number of subjects: 150
Study 19527280 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized fentanyl (NF) at 4 microg/kg
Number of subjects: 77
Study 19527280 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine (IVM) at 0.1 mg/kg
Number of subjects: 77
Study 18642378 — intervention group
Group type: EXPERIMENTAL
Intervention: Diathermy
Number of subjects: 35
Study 18642378 — intervention group
Group type: COMPARATOR
Intervention: Sham-diathermy
Number of subjects: 35
Study 18642378 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 35
Study 15613141 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (PPX)
Number of subjects: 41
Study 15613141 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide (PRG)
Number of subjects: 41
Study 15613141 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa therapy (as part of both interventions)
Number of subjects: 41
Study 12015621 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated rupture of the anterior cruciate ligament (group 1)
Number of subjects: 106
Study 12015621 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupture of the anterior cruciate ligament and accompanying joint damage (group 2)
Number of subjects: 106
Study 12015621 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 106
Study 10443307 — intervention group
Group type: EXPERIMENTAL
Intervention: Second harmonic imaging (SHI)
Number of subjects: 30
Study 10443307 — intervention group
Group type: COMPARATOR
Intervention: Fundamental imaging (FI)
Number of subjects: 30
Study 8551648 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN) for 2 weeks (group II)
Number of subjects: 0
Study 8551648 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition for 2 weeks (group III)
Number of subjects: 0
Study 8551648 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum oral diet for 2 weeks (group I)
Number of subjects: 0
Study 8551648 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN) for 2 weeks (group IV)
Number of subjects: 0
Study 2621333 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release salbutamol
Number of subjects: 52
Study 2621333 — intervention group
Group type: COMPARATOR
Intervention: Ordinary salbutamol
Number of subjects: 52
Study 831965 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose subcutaneous heparin
Number of subjects: 78
Study 831965 — intervention group
Group type: COMPARATOR
Intervention: Control (no heparin)
Number of subjects: 78
Study 831965 — intervention group
Group type: COMPARATOR
Intervention: Control (non-smokers)
Number of subjects: 78
Study 831965 — intervention group
Group type: COMPARATOR
Intervention: Control (smokers)
Number of subjects: 78
Study 30851727 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based multi-intervention (multi, n=30)
Number of subjects: 56
Study 30851727 — intervention group
Group type: COMPARATOR
Intervention: Standard care (stand, n=26)
Number of subjects: 56
Study 30851727 — intervention group
Group type: EXPERIMENTAL
Intervention: T2D patients (n=56)
Number of subjects: 56
Study 30851727 — intervention group
Group type: COMPARATOR
Intervention: Non-T2D controls (heart transplant donors, n=147)
Number of subjects: 56
Study 28603312 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based interventions (home-based counselling or women’s groups)
Number of subjects: 17
Study 25497250 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute stent (Medtronic Inc)
Number of subjects: 1391
Study 25497250 — intervention group
Group type: EXPERIMENTAL
Intervention: Xience V stent (Abbott Vascular)
Number of subjects: 1391
Study 25497250 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifurcation lesions
Number of subjects: 1391
Study 25497250 — intervention group
Group type: COMPARATOR
Intervention: Nonbifurcation lesions
Number of subjects: 1391
Study 23228946 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral-valve closed-system connector (Tego Needlefree Hemodialysis Connector)
Number of subjects: 66
Study 23228946 — intervention group
Group type: COMPARATOR
Intervention: Trisodium citrate, 46.7%, locking solution (Citra-Lock)
Number of subjects: 66
Study 20844946 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm and lubricant gel
Number of subjects: 955
Study 19406608 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer tailored physical activity intervention (n=563)
Number of subjects: 1171
Study 19406608 — intervention group
Group type: COMPARATOR
Intervention: Generic non-tailored intervention (n=608)
Number of subjects: 1171
Study 16753156 — intervention group
Group type: COMPARATOR
Intervention: Control group (current dose of rFSH)
Number of subjects: 60
Study 16753156 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-up group (additional 75 IU of rFSH)
Number of subjects: 60
Study 15153855 — intervention group
Group type: EXPERIMENTAL
Intervention: Altered cast impression procedure
Number of subjects: 72
Study 15153855 — intervention group
Group type: COMPARATOR
Intervention: One-piece cast
Number of subjects: 72
Study 11578889 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine, 0.2 mL/kg
Number of subjects: 96
Study 11578889 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% lidocaine, 0.2 mL/kg
Number of subjects: 96
Study 11578889 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine, 0.2 mL/kg
Number of subjects: 96
Study 11578889 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine, 0.3 mL/kg
Number of subjects: 96
Study 11578889 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine, 0.3 mL/kg
Number of subjects: 96
Study 11578889 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 96
Study 9040451 — intervention group
Group type: EXPERIMENTAL
Intervention: Low blood pressure goal (mean arterial pressure < or = 92 mm Hg)
Number of subjects: 585
Study 9040451 — intervention group
Group type: COMPARATOR
Intervention: Usual blood pressure goal (mean arterial pressure < or = 107 mm Hg)
Number of subjects: 585
Study 9040451 — intervention group
Group type: EXPERIMENTAL
Intervention: Low blood pressure goal
Number of subjects: 585
Study 9040451 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 585
Study 9040451 — intervention group
Group type: EXPERIMENTAL
Intervention: Low blood pressure goal for patients with urinary protein excretion > 1 g/d
Number of subjects: 585
Study 7935657 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (12 g daily)
Number of subjects: 106
Study 7935657 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil, similar dosage)
Number of subjects: 106
Study 3281724 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HDMTX)
Number of subjects: 0
Study 3281724 — intervention group
Group type: COMPARATOR
Intervention: RTSC (cranial irradiation and sequentially administered drug pairs)
Number of subjects: 0
Study 3281724 — intervention group
Group type: EXPERIMENTAL
Intervention: HDMTX
Number of subjects: 0
Study 3281724 — intervention group
Group type: COMPARATOR
Intervention: RTSC
Number of subjects: 0
Study 31706622 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium Hydroxide (Ca(OH)2)
Number of subjects: 66
Study 31706622 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium Hydroxide (Ca(OH)2) + Ibuprofen
Number of subjects: 66
Study 31706622 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium Hydroxide (Ca(OH)2) + Ciprofloxacin
Number of subjects: 66
Study 28271228 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam syrup 0.5 mg/kg
Number of subjects: 90
Study 28271228 — intervention group
Group type: COMPARATOR
Intervention: Intranasal midazolam spray 0.2 mg/kg
Number of subjects: 90
Study 25773607 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab (140 mg every 2 weeks or 420 mg monthly) plus standard therapy
Number of subjects: 4465
Study 25773607 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 4465
Study 21564309 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching (dorsiflexion to end ROM and holding for 1 min, five times)
Number of subjects: 11
Study 20457590 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily
Number of subjects: 56
Study 20457590 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir 300/100 mg plus omeprazole
Number of subjects: 56
Study 20457590 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir 400/100 mg plus omeprazole
Number of subjects: 56
Study 20457590 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 56
Study 19025944 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadoversetamide (OptiMARK) at doses of 0.05, 0.1, 0.2, or 0.3 mmol/kg
Number of subjects: 577
Study 17161766 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCT) doses (6.25 mg, 12.5 mg, or 25 mg) and extended release (ER) metoprolol doses (25 mg, 50 mg, 100 mg, 200 mg)
Number of subjects: 1571
Study 17161766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1571
Study 12705304 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate functional loading of Brånemark System implants (development group)
Number of subjects: 34
Study 12705304 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-stage implants (development group)
Number of subjects: 34
Study 12705304 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified protocol (simplified treatment group)
Number of subjects: 34
Study 12705304 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthesis (both groups)
Number of subjects: 34
Study 11115260 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy or tap biopsy for initial management of endophthalmitis
Number of subjects: 0
Study 11115260 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical repair of retinal detachment
Number of subjects: 0
Study 11115260 — intervention group
Group type: COMPARATOR
Intervention: No retinal detachment
Number of subjects: 0
Study 9187435 — intervention group
Group type: EXPERIMENTAL
Intervention: MACOP-B
Number of subjects: 236
Study 9187435 — intervention group
Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 236
Study 1286503 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (maximum dose, 30 ml providing 3 mg of flumazenil)
Number of subjects: 326
Study 1286503 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maximum dose, 30 ml)
Number of subjects: 326
Study 1286503 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (open-label after double-blind phase)
Number of subjects: 326
Study 1286503 — intervention group
Group type: COMPARATOR
Intervention: Placebo (open-label after double-blind phase)
Number of subjects: 326
Study 1286503 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 326
Study 3518019 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine
Number of subjects: 13
Study 29952033 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-piece implant system (BRA)
Number of subjects: 60